Gaudium IVF IPO
Gaudium IVF IPO Listing Day Performance
Gaudium IVF listed on BSE & NSE on 27 February 2026 at ₹83.00, a 5.06% premium over the issue price of ₹79. A retail investor allotted one lot of 189 shares gained ₹756 at the listing price.
GMP vs actual listing
| Last GMP before listing | ₹-4 (-5.1%) |
| GMP-implied listing | ₹75 |
| Actual listing | ₹83.00 |
| Difference | +₹8 (+10.7%) |
Demand going into listing
| Subscribed overall | 7.27× |
| QIB | 1.62× |
| NII | 14.05× |
| Retail | 7.6× |
Market Sentiment
IPO Details
Market Lot Size
IPO Reservation
Financial Analysis
Financial Data
Financial Performance
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 44.26 | 48.15 | 70.96 |
| Expense | 25.95 | 31.52 | 45.54 |
| Profit (PAT) | 13.53 | 10.32 | 19.13 |
| Total Assets | 36.63 | 51.01 | 88.51 |
Promoters & Holding Pattern
Promoters: Dr. Manika Khanna, Dr. Peeyush Khanna and Vishad Khanna
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 6,13,94,384 | 99.99% |
| Promoter Holding Post Issue | 7,27,86,884 | 71.30% |
Strengths & Risks
- Strongly subscribed — 7.3x overall (final).
- Revenue grew 47% in the latest reported year.
- Solid profit margin — 27.0%.
- Strong return on equity — 41%.
Our data checks haven't flagged a specific concern for Gaudium IVF — but that isn't a clean bill of health. Read the risk-factors section of the RHP, which lists company-specific risks our data can't capture.
From this issue's live data. Not investment advice — read the RHP.
Company Information
Gaudium IVF at a glance
From the company's description: “Gaudium IVF, founded in March 2015, is one of the leading companies offering In Vitro Fertilization (IVF) treatments for women across India.”
Gaudium IVF is raising ₹165 crore through an IPO on the BSE and NSE mainboard. Of that, ₹90 crore is a fresh issue — new shares, with the money going to the company — and ₹75 crore is an offer for sale by existing shareholders, who keep those proceeds; 55% of the issue therefore reaches the business. Main stated uses of the fresh money: Funding capital expenditure towards establishment of New IVF Centers of the Company (₹50 crore) and Repayment/pre-payment, in full or in part, of certain outstanding loans availed by our Company; and (₹20 crore).
Revenue went from ₹44.26 crore in 2023 to ₹70.96 crore in 2025, up 60% over 2 years. Profit after tax went from ₹13.53 crore to ₹19.13 crore, a net margin of 27% in the latest year.
The promoters, Dr. Manika Khanna and Dr. Peeyush Khanna and Vishad Khanna, hold 100% before the issue and 71% after it — a dilution of 28.7 percentage points. Debt stands at 0.41 times equity.
Written from the issue's offer-document figures shown on this page. Not investment advice.
Company Contact Information
Gaudium IVF & Women’s Health Ltd., B1/51,, Janak Puri,, B-1,, New Delhi, New Delhi, 110058
Objects of the Issue
| Purpose | Amount (Cr) |
|---|---|
| Funding capital expenditure towards establishment of New IVF Centers of the Company | 50.00 |
| Repayment/pre-payment, in full or in part, of certain outstanding loans availed by our Company; and | 20.00 |
| General Corporate Purpose | - |
Resources & Documents
Anchor Investors
Gaudium IVF IPO - Quick Take
Gaudium IVF has set a price band of Rs 75–Rs 79 per share for an issue size of Rs 165 crore. The stock listed with a 5.06% gain versus its issue price on February 27, 2026.
The issue is promoted by Dr. Manika Khanna, Dr. Peeyush Khanna and Vishad Khanna with Sarthi Capital Advisors Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards funding capital expenditure towards establishment of New IVF Centers of the Company (Rs 50 crore) and repayment/pre-payment, in full or in part, of certain outstanding loans availed by our Company; and (Rs 20 crore).
On fundamentals, the company is posting revenue growth of 47.4%, a profit margin of 27.0%, return on equity of 41.3% in its most recent reported period.
On our data-signal score, the combined signals for this issue currently read mixed — some indicators read positively and others do not. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Gaudium IVF IPO: Lead Manager & Registrar Track Record
How the firm running this issue and its registrar have fared on the other IPOs we track. Each firm's figures leave out Gaudium IVF itself, so they describe what came before it.
- Gaudium IVF listed at +5.1% on day one; the median of 113 listings was +7% (better than 44% of them).
- Subscribed 7.27x against a median of 20.56x across 111 issues (higher than 39%).
- Average listing-day move across all 114 Mainboard listings we track: +13.6%.
| Firm | Other IPOs | Listed at / above issue | Avg move | Median |
|---|---|---|---|---|
| Sarthi Capital Advisors Pvt. Ltd. Lead manager | 1 1 MB · 0 SME | 100% 1 of 1 | +31.1% | +31.1% |
| Bigshare Services Pvt. Ltd. Registrar | 61 18 MB · 43 SME | 67% 41 of 61 | Check allotment → | |
Recent listings managed by Sarthi Capital Advisors Pvt. Ltd. (1)
| IPO | Listed | Listing-day move |
|---|---|---|
| Jindal Supreme | 23 Sep 2026 | +31.1% |
A SEBI-registered merchant banker that runs the issue: due diligence, drafting the offer document, setting the price band with the company, and marketing the IPO to investors.
Finalises the basis of allotment, credits shares to demat accounts, releases blocked funds for unsuccessful bids and handles investor queries about the issue.
Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Counts cover IPOs we track only. Past listings don't predict this one; this is not investment advice.
Frequently Asked Questions
Gaudium IVF IPO GMP — What It Means
Its last GMP before listing was -5.1%. Of the 15 Mainboard IPOs we have tracked with a final GMP below zero, 2 listed above, 0 flat and 13 below the issue price; Gaudium IVF listed 5.1% above its issue price.
See the full Gaudium IVF GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
Same sector or same stage as Gaudium IVFNo comments yet. Be the first to share your opinion!